Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial

American Journal of Geriatric Psychiatry

Volumn 14, Issue 8, 2006, Pages 704-715

  Peskind, Elaine R ^a,f   Potkin, Steven G ^b   Pomara, Nunzio ^c   Ott, Brian R ^d   Graham, Stephen M ^e   Olin, Jason T ^e   McDonald, Scott ^e  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d BROWN UNIVERSITY   (United States)

^e FOREST RESEARCH INSTITUTE   (United States)

^f VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Alzheimer disease; Dementia; Memantine

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; CHOLINESTERASE INHIBITOR; DIURETIC AGENT; DONEPEZIL; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; TOCOPHEROL;

ADULT; AGITATION; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ALZHEIMER DISEASE COOPERATIVE STUDY ACTIVITIES OF DAILY LIVING INVENTORY; ARTICLE; BEHAVIOR; CLINICAL TRIAL; CLINICIAN INTERVIEW BASED IMPRESSION OF CHANGE PLUS CAREGIVER INPUT; COGNITION; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DIVERTICULITIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FALLING; FEMALE; FLU LIKE SYNDROME; FUNCTIONAL STATUS; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERTENSION; INJURY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NEUROPSYCHIATRIC INVENTORY; NON INVASIVE MEASUREMENT; OUTPATIENT; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; SYNCOPE; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 33746924907     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.JGP.0000224350.82719.83     Document Type: Article

References (22)

1. Hebert LE, Scherr PA, Bienias JL, et al: Alzhelmer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60:1119-1122
2. Cummings JL, Cole G: Alzheimer disease. JAMA 2002; 287:2335-2338
3. Selkoe DJ: The molecular pathology of Alzheimer's disease. Neuron 1991; 6:487-498
4. Parsons CG, Danysz W, Quack G: Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 1999; 38:735-767
5. Reisberg B, Doody R, Stöffler A, et al: Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348:1333-1341
6. Tariot PN, Farlow MR, Grossberg GT, et al: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291:317-324
7. Winblad B, Poritis N: Memantine in severe dementia: results of the M-BEST Study (Benefit and Efficacy in Severely demented patients during Treatment with memantine). Int J Geriatr Psychiatry 1999; 14:135-146
8. Orgogozo JM, Rigaud AS, Stöffler A, et al: Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM300). Stroke 2002; 33:1834-1939
9. Wilcock G, Möbius HJ, Stöffler A: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002; 17:297-305
10. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944
11. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state.' A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
12. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389
13. Rosen WG, Terry RD, Fuld PA, et al: Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980; 7:486-488
14. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC, American Psychiatric Association, 1994.
15. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141:1356-1364
16. Schneider LS, Olin JT, Doody RS, et al: Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2): S22-S32
17. Stern RG, Mohs RC, Davidson M, et al: A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994; 151:390-396
18. Weyer G, Erzigkeit H, Kanowski S, et al: Alzheimer's Disease Assessment Scale: reliability and validity in a multicenter clinical trial. Int Psychogeriatr 1997; 9:123-138
19. McLendon BM, Doraiswamy PM: Defining meaningful change in Alzheimer's disease trials: the donepezil experience. J Geriatr Psychiatry Neurol 1999; 12:39-48
20. Pena-Casanova J: Alzheimer's Disease Assessment Scale-cognitive in clinical practice. Int Psychogeriatr 1997; 9(suppl 1):105-114
21. Cummings JL, Mega M, Gray K, et al: The Neuropsychiatric Inventory: comprehensive assesisment of psychopathology in dementia. Neurology 1994; 44:2308-2314
22. Galasko D, Bennett D, Sano M, et al: An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2):S33-S39